Infants o1 year of age have a high prevalence of prognostically unfavorable leukemias and a presumed susceptibility to treatment-related toxicities. A total of 125 infants with acute myeloid leukemia (AML) were treated in studies AML-BFM-98 (n ¼ 59) and -2004 (n ¼ 66). Treatment regimens of both studies were comparable, consisting of intensive induction followed by four courses (mainly high-dose cytarabine and anthracyclines). Allogeneic-hematopoietic stem-cell-transplantation (allo-HSCT) in 1st remission was optional for high-risk (HR) patients. Most infants (120/125 ¼ 96%) were HR patients according to morphological, cytogenetic/molecular genetic and response criteria. Five-year overall survival was 66±4%, and improved from 61±6% in study-98 to 75±6% in study-2004 (P logrank 0.14) and event-free survival rates were 44±6% and 51±6% (P logrank 0.66), respectively. Results in HR infants were similar to those of older HR children (1-o2-or 2-o10-year olds, P logrank 0.90 for survival). Survival rates of HSCT in 1st remission, initial partial response and after relapse were high (13/14, 2/8 and 20/30 patients, respectively). The latter contributes to excellent 5-year survival after relapse (50±8%). Despite more severe infections and pulmonary toxicities in infants, treatment-related death rate was identical to that of older children (3%). Our data indicate that intensive frontline and relapse AML treatment is feasible in infants, toxicities are manageable, and outcome is favorable.
Introduction
Infants o1 year of age with acute myeloid leukemia (AML) generally show features of intermediate and high-risk (HR) AML. 1, 2 Rearrangements of chromosome 11q23Frespectively of the mixed lineage leukemia (MLL) geneFare the most common abnormalities found in infants with AML or acute lymphoblastic leukemia (ALL), consistent with a prenatal origin of these leukemias. 3 Intensive treatment is required to achieve complete remission (CR) and long-term survival. Very young children are considered particularly vulnerable patients who may not tolerate intensive treatment and hold a high risk for long-term sequelae after intensive chemotherapy, cranial irradiation and even more after hematopoietic stem cell transplantation (HSCT). 4 Whereas it is well known that infants with ALL have worse outcome than older children, 5 it was suggested that this might not be the case in AML. 6, 7 During the past decade, prognosis improved not only in standardrisk (SR) but also in HR pediatric AML. 8 This report describes the improved outcome of 108 infants with AML treated on protocols AML-BFM-98 and -2004 in comparison with older children.
Patients and methods

Patients
Our analysis includes patients from Germany, Austria, Switzerland and the Czech Republic, with de novo AML diagnosed between July 1998 and March 2010, treated on protocols AML-BFM-98, -98-Interim (combined to AML-BFM-98) and -2004. Written informed consent from parents or guardians was obtained at study entry.
Out of 1155 patients o18 years enrolled (Down syndrome excluded), 125 were infants o1 year; 136 were 1-o2 and 354 were 2-o10 years old. The upper age limit was selected in order to exclude adolescents.
Bone marrow morphology and cytogenetics were centrally reviewed (D Reinhardt, Hannover, and J Harbott, Giessen, Germany). Cytogenetic analysis, as described, 9 was successfully done in 92% (n ¼ 563) of the included patients aged o10 years.
Treatment plan
Patients were treated on protocols AML-BFM-98, -98-Interim and -2004. 10, 11 Treatment regimens were largely similar (overview of study AML-BFM-2004, Figure 1 ). Induction with AIE (cytarabine, idarubicin, etoposide) was given in all studies, whereas ADxE (Dx ¼ liposomal daunorubicin) was only randomly assigned in study-2004. Drug dosage in infants was generally calculated according to the bodyweight instead of body surface; only for high-dose (HD) cytarabine was the m 2 -dose given age-adjusted (from 20 in o3-month-to 60% in 411-month-old children because of a reduced cytarabine clearance in this age group). 12 Allogeneic (allo)-HSCT from a matched family donor (in poor responders also from an unrelated donor) in 1st remission (CR1) was restricted to HR patients. Cranial irradiation with 12 or 15 Gy had to be postponed until the age of 15 months in order to reduce neurotoxicity. 11 Intrathecal cytarabine was given 12 times (11 Â in SR patients) in age-related dosage adjustments. The 98-Interim regimen, which was identical to the standard arm of study-2004, was applied after closure of study-98 (7/2003-2/ 2004 ) until start of study-2004.
Until 9/2001, relapses were treated on protocol AML-BFM-REZ-97, with a double induction regimen with intermediatedose cytarabine and liposomal daunorubicin, followed by HSCT after consolidation. 13 From October 2001, patients were enrolled in the international protocol relapsed AML-2001/01 with a randomized FLAG (fludarabine, cytarabine, granulocytecolony-stimulating factor) or FLAG/DNX (plus liposomal daunorubicin) induction. 14, 15 There were no major changes in supportive-care strategies between the studies. The protocol guidelines recommend general prophylaxis for pneumocystis carinii pneumonia, and also to consider prophylaxis against viridans group streptococci and antifungal prophylaxis. 16, 17 Definition and statistics SR group included all patients with AML FAB M1/2 and Auer rods, M3, M4eo, t(15;17)/PML-RARA, t(8;21)/AML1-ETO or inv(16)/CBFB/MYH1 with the exception of slow early responders with 45% bone-marrow blasts on day 15 (FAB M3 excluded). All others were considered HR patients.
CR was defined according to the CALGB criteria. 18 Survival and event-free survival (EFS) were calculated from date of diagnosis to death of any cause or last follow-up (survival) or until first event (EFS, failure to achieve remission, resistant leukemia, relapse, secondary malignancy or death of any cause). Probabilities of survival were estimated using the Kaplan-Meier method, with s.e. calculated according to Greenwood, 19 and were compared with the log-rank test. Cumulative incidence (CI) functions of relapse and secondary malignancy were constructed by the Kalbfleisch and Prentice method. 19 Functions were compared with the Gray's test. Cox regression analysis was used for multivariate analysis. Toxicity was assessed according to the NCI common toxicity criteria version 2.0 (http://ctep.cancer.gov/reporting).
Univariate analysis was conducted by the Wilcoxon test for quantitative variables and Fisher's exact test for qualitative variables. When frequencies were sufficiently high, w 2 statistics were used. Computations were performed using SAS (Statistical Analysis System Version 9.1, SAS Institute Inc., Cary, NC, USA).
Results
Patient characteristics
A total of 125 infants with AML (median age 0.6 years, interquartile range 0.3À0.7 years) were enrolled in studies AML-BFM-98 (n ¼ 59) and AML-BFM-2004 (n ¼ 66). Twelve neonates (11%) who presented during the first 4 weeks of life were included. Patient characteristics were similar in both studies (data not shown). Most infants (120/125 ¼ 96%) were classified as HR patients. Four of the five SR patients had favorable cytogenetics with inv (16) and one presented with t(15;17). Patient characteristics in infants aged 1-3, 4-6, 7-9 or 10-12 months were similar, with the exception that the five SR patients were all in the highest (10-12 months) age group. Table 1a shows the clinical and biological features in infants compared with the older cohorts. Infants and patients aged 1-o2 years had similar characteristics. In both cohorts the percentage of patients with hyperleukocytosis, FAB M4/M5 and FAB M7 subtypes, as well as initial CNS and extramedullary organ involvement (mainly of the skin), was significantly higher than in older children. According to cytogenetic data (Table 1b) , more than half of all patients o1 year of age showed a MLL gene rearrangement. In most of these patients t(9;11) was identified; however, unlike infant ALL, no t(4;11) was observed. MLL rearrangements were most frequent in o2-year olds and significantly less frequent in older children (Po0.001).
The median follow-up period was 5.1 (0.6-12.1) years for infants and 4.9 (0.3-12.2) years for the other age groups (1-o2 years and 2-o10 years).
Treatment results
Five-year survival in the total group (n ¼ 125) of infants was 69 ± 4%. Survival improved from study-98 to -2004 from 61±6% (n ¼ 59) to 75±6% (n ¼ 66), P logrank 0.14 ( Figure 2a) . EFS rates were 44 ± 6% and 51 ± 6% (P logrank 0.66), respectively )/mitoxantrone; IT, intrathecal therapy; R1, first random assignment; R2, second random assignment; R3, third random assignment.
Outcome in infants with AML U Creutzig et al ( Figure 2b ). A total of 43 patients relapsed (5-year CI 34 ± 5%), with no significant differences in both studies (CI 37 ± 6% vs 33 ± 6%, P (Gray) 0.58). CNS relapse occurred in 14 patients (in 6 of them after initial CNS involvement); 6 relapses were combined with blasts in the bone marrow and 8 isolated in the CNS. Eight of the 14 CNS relapses were very early relapses (that is, within 6 months after diagnosis, before CNS irradiation was scheduled (nevertheless, 1 patient got irradiation)), the other 6 occurred later (in 2 of 36 irradiated and 3 of 44 non-irradiated patients with an EFS 46 months). 
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Results according to age groups
There was no difference in survival, EFS and CI for relapse in infants aged 0-3 (n ¼ 26), 4-6 (n ¼ 34), 7-9 (n ¼ 36) or 10-12 (n ¼ 29) months (Supplementary Figure S1 ). In addition, results of 12 newborns (7 of them diagnosed during the first 4 days of life) did not differ from those of older infants: continuous CR (n ¼ 7), early death (n ¼ 1), nonresponse (n ¼ 1), death in CCR (n ¼ 2) and relapse (n ¼ 1). When comparing EFS in infants with that in older children, EFS was significantly higher in children aged 2-o10 years than in those aged 1-o2 years and o1 year, respectively, P logrank 0.036 (Figure 3a) . However, the majority of patients o2 years of age were HR patients. Results for early death and nonresponse, 5-year survival, pEFS and CI of relapse were similar in HR infants and HR patients of the older age groups (1-o2 or 2-o10 years, Table 2 , Figure 3b ). The CI of death in remission (3%) and secondary malignancies were also similar. Only the rate of relapses with CNS involvement was higher in infants and 1-o2 year-old children than in 2-10-year-old children (Table 2) . Survival after relapse in HR infants was 50 ± 8% and was thus higher than in older HR patients (although not significantly in 42-year-old children, Figure 4 ).
Results in cytogenetic subgroups. Results in HR infants
with or without MLL gene rearrangements were similar: EFS 43±6% vs 52±7%, P logrank 0.48, survival 71±7% vs 66±8%, P logrank 0.59, respectively (Supplementary Figure S2) . In addition, results in different MLL fusions (which comprised less numbers of patients) were not significantly different in the infant group (data not shown).
Hematopoietic stem cell transplantation. There was no difference in the number and percentage of patients undergoing HSCT in both studies. In total, 50 patients received an allo-HSCT: in CR1 n ¼ 14 (matched related: 7, unrelated: 7), after partial-/nonresponse n ¼ 8 and after relapse n ¼ 30 (2 after HSCT in CR1). Median age at transplantation for CR1 patients was 0.46 (0.4-1.7), for nonresponders 0.4 (0.3-0.8), and for relapse patients 1.1 (0.5-3.3) years, respectively. In all, 13 of 14 CR1 patients survived. Two children relapsed and one developed a secondary malignancy. Two of 8 patients transplanted after initial non-/partial response and 20/30 patients transplanted after relapse are still alive.
Secondary malignancy
Two patients developed secondary malignancies (10 year CI 5 ± 3%). One case presented as T-ALL after 5.7 years and is still 
Toxicity
The rate of grade III/IV acute toxicities after induction was highest in infants and decreased in the age groups of 1-o2 and 2-o10 years: general condition 50% vs 43% vs 31% (P w 2 0.007); severe infection 42% vs 33% vs 29% (P w 2 0.08); pulmonary problems, including ventilation support 34% vs 24% vs 14% (P w 2 0.01). Severe mucositis occurred less often than in older children. There were three infants with cardiac arrhythmias, however, only one of them showed cardiac dysfunction ( Table 3 ). The cumulative incidence of late effects out of 67/81 (83%) infants surviving at least 1.5 years was not statistically different for patients with or without HSCT (59 ± 11% vs 43 ± 9%, P (Gray) 0.39).
Multivariate analysis
In a Cox regression analysis of EFS and survival, the following risk factors were included: age (o1 and 1-o2 years), hyperleukocytosis (X100 000/ml), blast count after induction (45%), favorable cytogenetics, MLL (t(9;11), t(11;19), other MLL), very HR cytogenetics/molecular genetics (definition see Table 4 ) and HSCT as a time-dependent covariable. Only blast count after induction 45% and favorable cyto-/molecular genetics were of prognostic significance; HSCT was significant for EFS but not for survival (Table 4) . In a Cox model for EFS in infants including the same variables with the age groups 0-o6 vs 6-o12 months as covariables, the latter was not significant.
Discussion
Results of studies AML-BFM-98 and -2004 show that the outcome in infants could be improved compared with the earlier studies, 20 leading to a 5-year survival rate of 75% in study AML-BFM-2004 . These results further demonstrate that intensive AML treatment is feasible and toxicities are manageable in this young age group. Importantly, even a second intensive salvage therapy after non-response and relapse can successfully be performed, resulting in a 5-year survival rate of 50% after relapse.
The achieved outcome data are excellent because infants and 1-2-year-old children with AML exhibited mainly unfavorable clinical and cyto-/molecular genetic risk factors (Tables 1a  and b) . 2, 20 Against this background, 1-2-year-olds were separately compared with older children. They present significantly more often with hepatosplenomegaly and extramedullary organ involvement and show a high incidence of the FAB subtypes M4/M5 and M7. This correlates with the high frequency of 11q23 or MLL rearrangements 21 and leads to the predominance of HR patients in this cohort. Patients with favorable cytogenetics were rarely reported. 2 We did not see any infant with t(8;21) and only 1 patient with t(15;17), which is very unusual. 22, 23 Inversion 16 was found in 4 infants, aged 49 months.
Results in studies AML-BFM-98 and -2004 were similar within the different age cohorts in infancy, and were also similar when (4) 64 (5) 66 ( Figure 4 Estimated probability of overall survival (pOS) after relapse in the high-risk groups of infants, 1-o2 year old and 2-o10 year old patients.
Outcome in infants with AML U Creutzig et al comparing them with older HR patients. There was also no difference in EFS between the studies. However, overall survival increased from study AML-BFM-98 to -2004 (Figure 2a) , which was partly due to better and more consequent treatment in initial non-/partial -responders, including HSCT after blast-cell reduction. In both studies, results after relapse were even better in infants than in older children (Figure 4 ). This was not expected and indicated that infants can tolerate intensive relapse treatment including HSCT. There was also an improved outcome for all AML children with MLL gene rearrangement in study-2004 compared with study-98. Recently, unlike in other patients, allo-HSCT in CR1 seemed to be beneficial for patients with 11q23 aberrations (Klusmann JH, in press). This fits to the good results after HSCT in CR1 in infants reported here and further indicates that acute toxicities can be better handled than in the past. 15 One problem in infants is the high rate of patients with CNS involvement, which may be due to the high frequency of monoblastic leukemias, as these cells are able to penetrate directly through the cytoplasm of the endothelial cells into the brain. 24 There is no satisfying treatment option, as cranial irradiation is associated with neurological late effects. In addition, CNS irradiation was performed late (in median 0.38 years after diagnosis) in our treatment schedules and CNS relapses occur much earlier than other relapses (median time to relapse 0.61 vs 1.1 years). Triple intrathecal therapy may be an option, because low rates of CNS relapses have been reported. 25 Acute toxicities in infants, apparent by the early death rate, were unacceptably high in the past (15% in patients o2 years in studies AML-BFM-83/87) 26 and remained slightly higher than in older patients; however, considering the high percentage of infants with hyperleukocytosis, there was no difference in the older age group. 26 Compared to older children acute toxicities in infants during induction chemotherapy were higher, concerning severe infections and pulmonary toxicities (earlier and more frequent respiratory support was necessary, probably due to a higher pulmonary susceptibility and less tolerance to compensate ventilation problems in infants). 27 This also indicates that close monitoring of the pulmonary condition is required. However, the toxic death rate during intensive chemotherapy and after HSCT was in the same range. Even in neonates intensive chemotherapy was successfully applied, which may be also because of the age-related dosage adjustments of cytarabine, 12 thus avoiding too much toxicity. Late effects concerning especially neurological/psychological impairments have been reported in both, the non-transplant as well as in the transplant infant group. A high rate of severe late effects after HSCT, for example, growth-hormone deficiency, hypothyroidism, abnormal pubertal development, osteopenia/ osteoporosis, short stature, dental abnormalities and cataracts, were described in young survivors of pediatric HSCT. 4, 28, 29 In addition, radiation-induced neuropsychological sequelae should be considered in very young patients. In our studies, cranial irradiation was postponed until the age of 15 months for these anticipated late effects and performed in a minority of patients. Long-term data on CNS toxicity are not yet available for the current infant group, however, the previous analysis from study AML-BFM-87 has shown a tendency toward more learning Abbreviations: EFS, event-free survival; HSCT*, hematopoietic stem cell transplantation as a time-dependent covariable; RR, risk ratio; ; MLL, mixed lineage leukemia; OS, overall survival; VHR, very high cytogenetics (definition: patients without favorable cytogenetics and at least one of the following aberration: t(9;22)(q34;q11), t(7;12)(q36;p13), t(4;11)(q21;q23), t(6;11)(q27;q23), t(6;9)(p23,q24), t(8;16)(p11;q13), -7, -12p); WBC, white blood cell count. Significant values are highlighted in bold. Outcome in infants with AML U Creutzig et al problems (deficits in concentration) in irradiated patients aged o5 years. 30 In view of these considerations, the aim should be to optimize treatment for infants with AML, applying the most effective treatment with the lowest side effects. 25, 31, 32 This implies to use HSCT in CR1 only in selected patients in whom a clear benefit can be expected (further analyses with higher number of patients are needed to define this group). In addition, in future AML-BFM studies, CNS irradiation will be substituted by triple-intrathecal therapy.
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In comparison with the favorable outcome of infants with AML, infants with ALL have a dismal prognosis (EFS 40±9% vs 84 ± 1% in children aged 1-5 years), which is explained by the high MLL incidence of 80% (EFS 40±10% in MLL-ALL). 33, 34 Besides all types of MLL rearrangements, an age of o6 months was an independent risk factor in ALL. In contrast to ALL, MLLpositivity was not an unfavorable risk factor in infant AML, which might be due to different fusion partners of this gene in AML and ALL (for example, t(4;11) was not found in our AML patient populations). In addition, very young age was neither an independent nor an associated risk factor for EFS in AML. In this context, it has to be mentioned that the cumulative doses of cytarabine and antracyclines were much lower in the ALL regimens (for example, in the INTERFANT-99 regimen) than in the AML treatment. Nevertheless, similar toxicities occurred during ALL-regimens. 34 Concerning other pediatric AML studies, experiences were similar. Five-year EFS rates for infants with AML were generally o50% for patients treated during the 80s and 90s until 1995 and improved during the late 90s. 29 A superior outcome (3-year EFS: 72%) in 35 infants with AML treated with three high-dosecytarabine courses was reported from Japan. 6 Data from the children cancer study group were favorable in infants regarding survival after CR (71% with allo-HSCT, 61% chemotherapy alone). 35 The British Medical Research Council showed a 5-year EFS of 59% in 57 AML infants, 7 and the Nordic Society for Paediatric Haematology and Oncology showed a 5-year EFS of 44 % in 25 infants. 36 It is difficult to compare these results, because of various criteria, for example, shorter follow-ups or presenting only results after CR or possible exclusion of neonates or early deaths.
In summary, the outcome of pediatric AML HR patients, after both frontline and relapse treatment, has improved considerably over the last 10-15 years. This has translated into an improved outcome in infants with AML. Intensive AML treatment is feasible in this young cohort, and toxicities are manageable. The favorable outcome is partly due to improved supportive care and better salvage therapy after nonresponse and relapse.
